Sacyr Valuation
Is 0OFU undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0OFU when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0OFU (€3.09) is trading above our estimate of fair value (€1.15)
Significantly Below Fair Value: 0OFU is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0OFU?
Key metric: As 0OFU is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 0OFU's PS Ratio? | |
|---|---|
| PS Ratio | 0.5x |
| Sales | €4.64b |
| Market Cap | €2.39b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.2x |
| Enterprise Value/EBITDA | 7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 0OFU's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.5x | ||
BBY Balfour Beatty | 0.3x | 8.1% | UK£2.3b |
MGNS Morgan Sindall Group | 0.4x | 3.2% | UK£1.8b |
KLR Keller Group | 0.4x | 3.1% | UK£1.1b |
RNWH Renew Holdings | 0.8x | 6.0% | UK£823.0m |
0OFU Sacyr | 0.5x | 1.7% | €2.4b |
Price-To-Sales vs Peers: 0OFU is expensive based on its Price-To-Sales Ratio (0.5x) compared to the peer average (0.5x).
Price to Sales Ratio vs Industry
How does 0OFU's PS Ratio compare vs other companies in the European Construction Industry?
| 11 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 11 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 0OFU is expensive based on its Price-To-Sales Ratio (0.5x) compared to the European Construction industry average (0.4x).
Price to Sales Ratio vs Fair Ratio
What is 0OFU's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.5x |
| Fair PS Ratio | 2.7x |
Price-To-Sales vs Fair Ratio: 0OFU is good value based on its Price-To-Sales Ratio (0.5x) compared to the estimated Fair Price-To-Sales Ratio (2.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €3.09 | €4.16 +34.5% | 6.2% | €4.45 | €3.50 | n/a | 11 |
| Nov ’25 | €3.08 | €4.19 +35.9% | 6.2% | €4.45 | €3.50 | n/a | 11 |
| Oct ’25 | €3.25 | €4.09 +25.8% | 7.3% | €4.45 | €3.50 | n/a | 12 |
| Sep ’25 | €3.26 | €4.09 +25.5% | 7.6% | €4.45 | €3.50 | n/a | 11 |
| Aug ’25 | €3.16 | €4.09 +29.7% | 7.6% | €4.45 | €3.50 | n/a | 11 |
| Jul ’25 | €3.34 | €4.12 +23.4% | 6.3% | €4.40 | €3.53 | n/a | 10 |
| Jun ’25 | €3.44 | €4.02 +16.9% | 6.5% | €4.40 | €3.53 | n/a | 9 |
| May ’25 | €3.28 | €3.85 +17.3% | 7.1% | €4.20 | €3.40 | n/a | 10 |
| Apr ’25 | €3.36 | €3.82 +13.6% | 7.2% | €4.20 | €3.40 | n/a | 9 |
| Mar ’25 | €3.04 | €3.85 +26.5% | 7.1% | €4.20 | €3.40 | n/a | 10 |
| Feb ’25 | €3.07 | €3.76 +22.5% | 9.2% | €4.20 | €3.15 | n/a | 9 |
| Jan ’25 | €3.11 | €3.76 +21.0% | 9.2% | €4.20 | €3.15 | n/a | 9 |
| Dec ’24 | €3.09 | €3.77 +22.0% | 9.1% | €4.20 | €3.15 | n/a | 9 |
| Nov ’24 | €2.71 | €3.70 +36.5% | 9.1% | €4.10 | €3.15 | €3.08 | 8 |
| Oct ’24 | €2.79 | €3.68 +32.1% | 8.7% | €4.10 | €3.15 | €3.25 | 8 |
| Sep ’24 | €2.94 | €3.67 +24.9% | 8.7% | €4.10 | €3.15 | €3.26 | 8 |
| Aug ’24 | €3.03 | €3.67 +21.2% | 8.7% | €4.10 | €3.15 | €3.16 | 8 |
| Jul ’24 | €3.13 | €3.67 +17.3% | 8.7% | €4.10 | €3.15 | €3.34 | 8 |
| Jun ’24 | €2.83 | €3.56 +25.9% | 6.8% | €4.00 | €3.15 | €3.44 | 9 |
| May ’24 | €2.99 | €3.55 +18.5% | 6.8% | €4.00 | €3.15 | €3.28 | 9 |
| Apr ’24 | €2.96 | €3.49 +18.0% | 6.8% | €3.85 | €3.15 | €3.36 | 9 |
| Mar ’24 | €3.04 | €3.49 +14.8% | 6.8% | €3.85 | €3.15 | €3.04 | 9 |
| Feb ’24 | €2.85 | €3.48 +22.3% | 7.1% | €3.85 | €3.12 | €3.07 | 9 |
| Jan ’24 | €2.61 | €3.48 +33.6% | 7.1% | €3.85 | €3.12 | €3.11 | 9 |
| Dec ’23 | €2.65 | €3.48 +31.6% | 7.1% | €3.85 | €3.12 | €3.09 | 9 |
| Nov ’23 | €2.49 | €3.52 +41.3% | 6.4% | €3.80 | €3.11 | €2.71 | 8 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Aalberts
€4.0b
Offers mission-critical technologies for aerospace, automotive, building, and maritime sectors.
0NX1
€36.44
7D
7.0%
1Y
0.08%
INDUS Holding
€558.5m
A private equity firm specializing in mergers and acquisitions and corporate spin-offs.
0EUH
€21.70
7D
1.9%
1Y
5.6%
Palfinger
€674.5m
Produces and sells crane and lifting solutions worldwide.
0MJ1
€19.59
7D
-0.2%
1Y
-15.4%